Evan Y. Snyder earned his M.D. and Ph.D. in neuroscience from the University of Pennsylvania (PA, USA) as a member of National Institutes of Health Medical Scientist Training Program (MSTP). He had also studied psychology and linguistics at the University of Oxford (Oxford, UK). He received all of this medical post-graduate training (in pediatrics, neurology, and neonatal-perinatal medicine) at Children's Hospital-Boston, Harvard Medical School (MA, USA) as well as a research post-doctoral fellowship in the Department of Genetics at Harvard Medical School, after which he became an attending physician in the Department of Pediatrics (Division of Newborn Medicine) and Department of Neurology at Children's Hospital-Boston, Harvard Medical School. He also established his own independent research program at Boston Children’s Hospital, Harvard Medical School and was appointed first as an instructor in neurology (neonatology) and then promoted to assistant professor where he helped launch the stem cell and regenerative medicine fields. He is regarded as one of the fathers of the stem cell and regenerative medicine fields. In 2003, after 23 years at Harvard, Dr. Snyder was recruited to Southern California, to Sanford-Burnham Prebys Medical Discovery Institute and University of California-San Diego (CA, USA) (Department of Pediatrics) as a Full Professor and Founding Director of the Center for Stem Cells & Regenerative Medicine. He then inaugurated the Stem Cell Research Center & Core Facility (serving as its founding director), initiated the Southern California Stem Cell Consortium (CA, USA), & helped found the Sanford (San Diego) Consortium for Regenerative Medicine. Dr. Snyder is a Fellow of the American Academy of Pediatrics (FAAP) and was elected to the Association of American Physicians (AAP). He was a founding member of the FDA/NIH Stem Cell Working Group to generate guidelines for human transplantation, and served nearly a decade on the FDA’s Biological Response Modifiers Advisory Committee with emphasis on stem cells, as well as serving two terms as Chair of the FDA’s Cell, Tissue, & Gene Therapy Advisory Committee. He is now Chairman of the Scientific Advisory Committee (SAC) of the Genetic Disease Biobank of the National Institute of General Medical Science (NIGMS) at NIH. He is a recent Diplomate of the select Health Leadership Academy.